58 related articles for article (PubMed ID: 31645348)
1. Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis.
Ruan GJ; Zanwar S; Ravindran A; Schram S; Abeykoon JP; Hazim A; Young JR; Shah MV; Bennani NN; Jiang L; Morlote D; Rech KL; Goyal G; Go RS;
Am J Hematol; 2024 May; 99(5):871-879. PubMed ID: 38409747
[TBL] [Abstract][Full Text] [Related]
2. A 43-Year-Old Female with Multifocal Cerebral Lesions. Histiocytic Sarcoma.
Nieuwenhuis MB; van der Salm SM; Verhoeff JJ; van der Kooi AJ; Slavujecvic-Letic I; Pals ST; Vos JM
Brain Pathol; 2015 May; 25(3):371-2. PubMed ID: 26086057
[No Abstract] [Full Text] [Related]
3. Two sides of the same coin: transdifferentiation from Burkitt lymphoma to histiocytic sarcoma.
Etancelin P; Boussaid I
Blood; 2023 Nov; 142(18):1576. PubMed ID: 37917080
[No Abstract] [Full Text] [Related]
4. CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition.
Diamond EL; Francis JH; Lacouture ME; Rotemberg V; Yabe M; Petrova-Drus K; Ulaner GA; Reddy R; Abdel-Wahab O; Durham BH
Leukemia; 2023 Aug; 37(8):1737-1740. PubMed ID: 37355734
[No Abstract] [Full Text] [Related]
5. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
[TBL] [Abstract][Full Text] [Related]
6. Oncohistones: Hijacking the histone code.
Sahu V; Lu C
Annu Rev Cancer Biol; 2022 Apr; 6():293-312. PubMed ID: 36589281
[TBL] [Abstract][Full Text] [Related]
7. Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.
Rajagopalan KN; Chen X; Weinberg DN; Chen H; Majewski J; Allis CD; Lu C
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619101
[TBL] [Abstract][Full Text] [Related]
8. Sarcoma treatment in the era of molecular medicine.
Grünewald TG; Alonso M; Avnet S; Banito A; Burdach S; Cidre-Aranaz F; Di Pompo G; Distel M; Dorado-Garcia H; Garcia-Castro J; González-González L; Grigoriadis AE; Kasan M; Koelsche C; Krumbholz M; Lecanda F; Lemma S; Longo DL; Madrigal-Esquivel C; Morales-Molina Á; Musa J; Ohmura S; Ory B; Pereira-Silva M; Perut F; Rodriguez R; Seeling C; Al Shaaili N; Shaabani S; Shiavone K; Sinha S; Tomazou EM; Trautmann M; Vela M; Versleijen-Jonkers YM; Visgauss J; Zalacain M; Schober SJ; Lissat A; English WR; Baldini N; Heymann D
EMBO Mol Med; 2020 Nov; 12(11):e11131. PubMed ID: 33047515
[TBL] [Abstract][Full Text] [Related]
9. Primary histiocytic sarcoma presenting as diffuse leptomeningeal disease: Case description and review of the literature.
Zanelli M; Ragazzi M; Marchetti G; Bisagni A; Principi M; Fanni D; Froio E; Serra S; Zanetti E; De Marco L; Giangaspero F; Ascani S
Neuropathology; 2017 Dec; 37(6):517-525. PubMed ID: 28548244
[TBL] [Abstract][Full Text] [Related]
10. Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review.
May JM; Waddle MR; Miller DH; Stross WC; Kaleem TA; May BC; Miller RC; Jiang L; Strong GW; Trifiletti DM; Chaichana KL; Reimer R; Tun HW; Peterson JL
Radiat Oncol; 2018 Sep; 13(1):167. PubMed ID: 30185195
[TBL] [Abstract][Full Text] [Related]
11. Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy.
Snuderl M; Dolgalev I; Heguy A; Walsh MF; Benayed R; Jungbluth AA; Ladanyi M; Karajannis MA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645348
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in histiocytic sarcoma identified by next generation sequencing.
Liu Q; Tomaszewicz K; Hutchinson L; Hornick JL; Woda B; Yu H
Virchows Arch; 2016 Aug; 469(2):233-41. PubMed ID: 27259537
[TBL] [Abstract][Full Text] [Related]
13. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
Lu C; Jain SU; Hoelper D; Bechet D; Molden RC; Ran L; Murphy D; Venneti S; Hameed M; Pawel BR; Wunder JS; Dickson BC; Lundgren SM; Jani KS; De Jay N; Papillon-Cavanagh S; Andrulis IL; Sawyer SL; Grynspan D; Turcotte RE; Nadaf J; Fahiminiyah S; Muir TW; Majewski J; Thompson CB; Chi P; Garcia BA; Allis CD; Jabado N; Lewis PW
Science; 2016 May; 352(6287):844-9. PubMed ID: 27174990
[TBL] [Abstract][Full Text] [Related]
14. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
[TBL] [Abstract][Full Text] [Related]
15. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Shanmugam V; Griffin GK; Jacobsen ED; Fletcher CDM; Sholl LM; Hornick JL
Mod Pathol; 2019 Jun; 32(6):830-843. PubMed ID: 30626916
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
